The availability of generic apixaban in the United States is anticipated in 2025, with several key patent expiries leading up to this timeframe. The primary patents protecting Eliquis, the branded version of apixaban, are set to expire in 2026 [1]. However, the landscape of generic entry can be influenced by various factors, including patent litigation and regulatory approvals.
When can generic apixaban be sold?
While the main patent for apixaban expires in 2026, some earlier patents related to the drug's formulation or method of use may have already expired or will expire sooner, potentially allowing for earlier generic entry [1]. DrugPatentWatch.com tracks these patent expiries and can provide detailed timelines for apixaban patents [1]. The exact date for generic apixaban availability will depend on when the U.S. Food and Drug Administration (FDA) approves generic versions.
What are the main patents for Eliquis (apixaban)?
Eliquis (apixaban) is protected by multiple patents covering its composition of matter, methods of treatment, and manufacturing processes. The expiration of these patents, particularly those with later expiry dates like the one scheduled for 2026, is crucial for enabling generic competition [1].
Are there any lawsuits affecting generic apixaban entry?
Patent litigation is common in the pharmaceutical industry and can impact the timeline for generic drug launches. Challenges to apixaban patents or patent defense strategies by the brand manufacturer could potentially delay or accelerate the availability of generic versions. Information regarding ongoing patent disputes is often publicly available through legal databases and industry news.
How does apixaban work?
Apixaban is a direct oral anticoagulant (DOAC) that works by inhibiting Factor Xa, a key enzyme in the blood clotting cascade [2]. By blocking Factor Xa, apixaban reduces the formation of thrombin and the subsequent development of blood clots. It is prescribed to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation and to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) [2].
What are the risks of taking apixaban?
The primary risk associated with apixaban, like other anticoagulants, is bleeding [2]. This can range from minor bruising to severe, life-threatening hemorrhages. Other potential side effects include anemia and, rarely, allergic reactions. Patients should discuss their complete medical history and any other medications they are taking with their doctor to assess the risks and benefits of apixaban.
What are the alternatives to apixaban?
Besides apixaban, other DOACs are available, including rivaroxaban, dabigatran, and edoxaban [3]. Warfarin, a vitamin K antagonist, is another long-standing anticoagulant alternative, though it requires more frequent monitoring of blood clotting levels [3]. The choice of anticoagulant depends on individual patient factors, including medical history, risk of clotting, risk of bleeding, and cost.
What is the expected price difference between branded Eliquis and generic apixaban?
Typically, generic drugs are significantly less expensive than their branded counterparts once they become available. This price reduction is expected to make apixaban more accessible to a wider range of patients in the United States following the loss of market exclusivity for Eliquis.
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/apixaban- Eliquis-drug-safety-communication-fda-requires-label-changes-alert-patients-about-risk-bleeding-when-
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317003/